Olainfarm Announces €100m Investment For Ten Products Every Year
In A Bid To Be Among Top Ten Firms In Central And Eastern Europe
Olainfarm has announced plans to find €100m in funding – including through increased efficiencies and reinvestment of profits – to invest in a five-year plan that will see it develop ten new products each year as part of efforts to become one of the top ten pharma players in Central and Eastern Europe.
You may also be interested in...
US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.
India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets.
Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.